FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043977100> ?p ?o ?g. }

• W2043977100 endingPage "283" @default.
• W2043977100 startingPage "283" @default.
• W2043977100 abstract "Neutropenic patients with cancer are traditionally treated with empiric antibiotic combinations when they become febrile. The availability of broad-spectrum antibiotics such as ceftazidime and imipenem has made it possible to initiate therapy with a single agent (monotherapy). The objectives of this trial were to compare ceftazidime and imipenem as single agents for the therapy of febrile episodes in neutropenic patients and to ascertain whether the addition of an aminoglycoside (amikacin) to either of these agents would provide an advantage.A prospective clinical trial was conducted in which eligible neutropenic patients with cancer were randomized to one of four treatment arms: ceftazidime alone; imipenem alone; ceftazidime plus amikacin; and imipenem plus amikacin. Efficacy analysis was done for 750 assessable episodes. A multivariate logistic-regression analysis was also performed to examine the unique contribution of various prognostic factors.The overall response rates were 76% with imipenem plus amikacin, 72% with imipenem, 71% with ceftazidime plus amikacin, and 59% with ceftazidime alone. Single-organism gram-positive infections occurred in 101 of 750 episodes. Without a change in antibiotics, the response rates were 50% with imipenem, 40% with imipenem plus amikacin, 39% with ceftazidime plus amikacin, and 38% with ceftazidime. Most responded to vancomycin or other antibiotics, and the mortality associated with gram-positive infections was only 5%. Regardless of the antibiotic regimen, the majority of uncomplicated gram-negative infections responded to therapy and the majority of complicated gram-negative infections failed to respond. Multivariate logistic-regression analysis showed that recovery of the neutrophil count was the most favorable prognostic factor in a patient's response to infection, whereas the presence of gram-positive infection, acute leukemia, pulmonary or enteric infection, and therapy with ceftazidime were unfavorable factors.Single-agent therapy with imipenem is as effective as more conventional combination antibiotic therapy for the empirical treatment of febrile episodes in neutropenic patients with cancer." @default.
• W2043977100 created "2016-06-24" @default.
• W2043977100 creator A5007152490 @default.
• W2043977100 creator A5008575977 @default.
• W2043977100 creator A5027575595 @default.
• W2043977100 creator A5030497065 @default.
• W2043977100 creator A5040486044 @default.
• W2043977100 creator A5047603773 @default.
• W2043977100 creator A5060386553 @default.
• W2043977100 creator A5064601215 @default.
• W2043977100 creator A5077560225 @default.
• W2043977100 creator A5082916862 @default.
• W2043977100 date "1992-02-01" @default.
• W2043977100 modified "2023-10-14" @default.
• W2043977100 title "A Comparison of Imipenem to Ceftazidime With or Without Amikacin as Empiric Therapy in Febrile Neutropenic Patients" @default.
• W2043977100 cites W1492940396 @default.
• W2043977100 cites W1968108660 @default.
• W2043977100 cites W1977109815 @default.
• W2043977100 cites W1982383227 @default.
• W2043977100 cites W1988723771 @default.
• W2043977100 cites W1991602522 @default.
• W2043977100 cites W1997620519 @default.
• W2043977100 cites W2002245589 @default.
• W2043977100 cites W2011743250 @default.
• W2043977100 cites W2014659750 @default.
• W2043977100 cites W2022252938 @default.
• W2043977100 cites W2035729126 @default.
• W2043977100 cites W2040060069 @default.
• W2043977100 cites W2042524579 @default.
• W2043977100 cites W2042610064 @default.
• W2043977100 cites W2044363049 @default.
• W2043977100 cites W2058434761 @default.
• W2043977100 cites W2072517403 @default.
• W2043977100 cites W2074184363 @default.
• W2043977100 cites W2082902788 @default.
• W2043977100 cites W2083544037 @default.
• W2043977100 cites W2090959569 @default.
• W2043977100 cites W2096104385 @default.
• W2043977100 cites W2151581642 @default.
• W2043977100 cites W2169078539 @default.
• W2043977100 cites W2314293608 @default.
• W2043977100 cites W2416023401 @default.
• W2043977100 cites W2995475181 @default.
• W2043977100 cites W3022798003 @default.
• W2043977100 cites W388523312 @default.
• W2043977100 doi "https://doi.org/10.1001/archinte.1992.00400140037010" @default.
• W2043977100 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1739355" @default.
• W2043977100 hasPublicationYear "1992" @default.
• W2043977100 type Work @default.
• W2043977100 sameAs 2043977100 @default.
• W2043977100 citedByCount "182" @default.
• W2043977100 countsByYear W20439771002012 @default.
• W2043977100 countsByYear W20439771002013 @default.
• W2043977100 countsByYear W20439771002014 @default.
• W2043977100 countsByYear W20439771002016 @default.
• W2043977100 countsByYear W20439771002018 @default.
• W2043977100 countsByYear W20439771002019 @default.
• W2043977100 countsByYear W20439771002020 @default.
• W2043977100 countsByYear W20439771002022 @default.
• W2043977100 countsByYear W20439771002023 @default.
• W2043977100 crossrefType "journal-article" @default.
• W2043977100 hasAuthorship W2043977100A5007152490 @default.
• W2043977100 hasAuthorship W2043977100A5008575977 @default.
• W2043977100 hasAuthorship W2043977100A5027575595 @default.
• W2043977100 hasAuthorship W2043977100A5030497065 @default.
• W2043977100 hasAuthorship W2043977100A5040486044 @default.
• W2043977100 hasAuthorship W2043977100A5047603773 @default.
• W2043977100 hasAuthorship W2043977100A5060386553 @default.
• W2043977100 hasAuthorship W2043977100A5064601215 @default.
• W2043977100 hasAuthorship W2043977100A5077560225 @default.
• W2043977100 hasAuthorship W2043977100A5082916862 @default.
• W2043977100 hasConcept C126322002 @default.
• W2043977100 hasConcept C177713679 @default.
• W2043977100 hasConcept C2776694085 @default.
• W2043977100 hasConcept C2776968632 @default.
• W2043977100 hasConcept C2777063308 @default.
• W2043977100 hasConcept C2777427914 @default.
• W2043977100 hasConcept C2777637488 @default.
• W2043977100 hasConcept C2779631663 @default.
• W2043977100 hasConcept C3019249092 @default.
• W2043977100 hasConcept C501593827 @default.
• W2043977100 hasConcept C523546767 @default.
• W2043977100 hasConcept C54355233 @default.
• W2043977100 hasConcept C71924100 @default.
• W2043977100 hasConcept C86803240 @default.
• W2043977100 hasConcept C89423630 @default.
• W2043977100 hasConcept C94665300 @default.
• W2043977100 hasConceptScore W2043977100C126322002 @default.
• W2043977100 hasConceptScore W2043977100C177713679 @default.
• W2043977100 hasConceptScore W2043977100C2776694085 @default.
• W2043977100 hasConceptScore W2043977100C2776968632 @default.
• W2043977100 hasConceptScore W2043977100C2777063308 @default.
• W2043977100 hasConceptScore W2043977100C2777427914 @default.
• W2043977100 hasConceptScore W2043977100C2777637488 @default.
• W2043977100 hasConceptScore W2043977100C2779631663 @default.
• W2043977100 hasConceptScore W2043977100C3019249092 @default.
• W2043977100 hasConceptScore W2043977100C501593827 @default.
• W2043977100 hasConceptScore W2043977100C523546767 @default.

• next